Table 3 Secondary and exploratory efficacy endpoints (modified intent-to-treat population)
Characteristics | IPE 4 g/day (n = 125) | IPE 2 g/day (n = 124) | Placebo (n = 124) | Placebo-corrected median change from baseline | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|  | Baseline Value | End-of-treatment Value | Change from baseline (%) | Baseline Value | End-of-treatment Value | Change from baseline (%) | Baseline Value | End-of-treatment Value | Change from baseline (%) | IPE 4 g/day vs. placebo (%, P Value) | IPE 2 g/day vs. placebo (%, P value) |
VLDL-C (mmol/L) (n = 121, 124, 123) | 2.850 (1.610) | 2.170 (1.560) |  − 17.20 (62.00) | 2.750 (1.985) | 2.875 (2.345) |  − 5.50 (77.60) | 3.030 (1.660) | 3.290 (2.290) | 9.60 (65.00) |  − 27.85, < 0.001 |  − 12.75, 0.059 |
LDL-C (mmol/L) (n = 121, 124, 123) | 1.430 (1.170) | 1.650 (1.360) | 11.80 (88.60) | 1.290 (1.170) | 1.755 (1.625) | 25.20 (93.60) | 1.350 (1.050) | 1.460 (1.150) | 3.80 (71.50) | 4.85, 0.475 | 14.80, 0.065 |
Non–HDL-C (mmol/L) (n = 121, 124, 123) | 4.690 (1.440) | 4.260 (1.410) |  − 6.60 (32.50) | 4.785 (1.900) | 4.900 (2.050) | 5.25 (32.55) | 4.690 (1.490) | 5.020 (1.860) | 8.80 (33.50) |  − 14.55, < 0.001 |  − 3.45, 0.284 |
VLDL-TG (mmol/L) (n = 121, 123,123) | 6.870 (5.880) | 4.630 (4.510) |  − 25.50 (63.70) | 6.890 (6.920) | 6.300 (7.380) |  − 12.00 (84.60) | 6.720 (5.680) | 6.760 (6.920) | 3.20 (83.80) |  − 25.15, < 0.001 |  − 12.55, 0.114 |